Within some seminal works, whole-exome sequencing of SCLC tumor surgical samples in a treatment-naïve population confirmed the already known genetic features of this disease, characterized by a high mutational burden (8.6 mut/Mb), universal loss-of-function mutations in TP53 and RB1 and rare actionable targetable mutations in KIT, PIK3CA, BRAF and amplification of FGFR1, SOX2 and MYC (9). Here, MYC is linked to small cell lung carcinoma.